- WG1 – THE ROLE OF INFLAMMATION IN CONGENITAL CNP
- WG2 – ACQUIRED AND LIKELY-ACQUIRED CNP AND INFLAMMATION
- WG3 – CNP RISK FACTOR PROFILING AND ML PREDICTIVE MODELING
- WG4 – DRUG-INDUCED NEUTROPENIAS BY NOVEL THERAPIES
- WG5 – GENERAL CONCEPT AND DESIGN OF CLINICAL TRIALS
- WG6 – DEVELOPMENT OF TOOLS FOR EVALUATION OF PROs AND QoL
LEADER
Dr Cornelia ZEIDLER
zeidler.cornelia@mh-hannover.de
Co-LEADERS
Dr Christina KARAMANIDOU
ckaramanidou@certh.gr
Dr Edward LAANE
edward.laane@ut.ee
How can I participate?
Read the Action Description MoU
Inform the Main Proposer/Chair of your interest (e.papadaki@uoc.gr)
Apply to join your Working Groups of interest
Please note, Management Committee nominations are carried out through the COST National Coordinators
DEVELOPMENT OF TOOLS FOR EVALUATION OF PROs AND QoL
The main objective of WG6 is to develop a comprehensive, validated PRO questionnaire designed to assess key aspects of QoL (and well-being) of CNP patients. The questionnaire will capture general and specific QoL dimensions, reflecting wellbeing, relevant to children and adults with CNPs.
Task 1: Systematic Review of QoL, Wellbeing, and Psychosocial Factors.
A systematic review will be conducted to identify and synthesize existing literature on QoL, well-being, and psychosocial aspects specific to CNP. It will provide an evidence-based foundation, mapping relevant studies and identifying gaps in existing research. The results will inform the selection of domains and constructs to be included in the questionnaire, ensuring that the tool addresses needs/experiences of CNP patients.
Task 2: Focus Group Discussions with Healthcare Professionals and Patients.
To ensure the questionnaire captures relevant themes from clinical and patient perspectives, a series of focus group discussions will be held. They will involve key stakeholders, including healthcare professionals and patients/families, to generate qualitative data on important QoL issues. Insights from these discussions will contribute to the development of a theme bank for the generation of the questionnaire.
Task 3: Pilot Study and Validation.
A pilot study will be conducted with CNP patients to assess the questionnaire’s readability, comprehensibility, content validity. Statistical analyses will be performed on the pilot data to examine the questionnaire’s structure and identify correlations/patterns within the responses. The pilot study will yield a refined, population-specific QoL assessment tool, with initial validation of its psychometric properties. In addition to refining the population-specific QoL assessment tool, the PROs will be structured into a digital format, resulting in electronic PROs (ePROs). These ePROs will enable seamless digital access for patients, allowing them to report their QoL and well-being via online platforms or mobile applications. This digital transformation will increase accessibility, ease of use, and real-time monitoring, providing healthcare professionals with timely insights into PRO. Initial validation of the ePROs will include an assessment of their reliability and usability in a digital environment, ensuring that they maintain robustness and accuracy.
Milestones
M6.1. WG Meetings (1st quarter of each year) which will be based on the development on the question bank following the focus groups meetings progress, pilot study data collection, development of questionnaire followed by the respective technical and scientific reports (months 12, 24,36, 48).
M6.2. Calls for STSMs (2nd and 4th quarter of each year) for training of YRIs on the development of ePRO followed by the respective technical and scientific reports (months 12, 24, 36, 48).
M6.3 Announcement of the development of the digital ePRO and data presentation through various dissemination activities (months 36,42,48).